Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01131169 · OUTCOME

Proportion of Participants With Relapsed Multiple Myeloma Alive at 2 Years

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions · Source last updated 2021-12-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Proportion of pts alive at 2 years
Interval / dispersion
95% Confidence Interval
Time frame
2 years

Analysis population: This objective is only for participants with relapsed multiple myeloma.

Groups in this outcome

Relapsed Multiple Myeloma

This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma

High-risk Multiple Myeloma

This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Relapsed Multiple Myeloma44
High-risk Multiple Myeloma0

Reported measurements

Source class 1
Values in Proportion of pts alive at 2 years · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Relapsed Multiple Myeloma0.54Not reported0.410.72Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.41
        upper Limit
        0.72
        value
        0.54
denoms
  1. counts
    1. group Id
      OG000
      value
      44
    2. group Id
      OG001
      value
      0
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma
    id
    OG000
    title
    Relapsed Multiple Myeloma
  2. description
    This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma
    id
    OG001
    title
    High-risk Multiple Myeloma
param Type
NUMBER
population Description
This objective is only for participants with relapsed multiple myeloma.
reporting Status
POSTED
time Frame
2 years
title
Proportion of Participants With Relapsed Multiple Myeloma Alive at 2 Years
type
SECONDARY
unit Of Measure
Proportion of pts alive at 2 years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice